Nicole Deis
Overview
Explore the profile of Nicole Deis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Villalobos M, Korezelidou A, Unsold L, Deis N, Thomas M, Siegle A
BMC Palliat Care
. 2025 Feb;
24(1):48.
PMID: 39979926
Background: The timely initiation of end-of-life (EOL) conversations is considerered best practice for patients with advanced cancer and therefore recommended in oncological guidelines. General practitioners (GPs) play a key role...
2.
Villalobos M, Unsold L, Deis N, Behnisch R, Siegle A, Thomas M
Dtsch Arztebl Int
. 2024 Dec;
121(26):861-867.
PMID: 39635949
Background: Advanced lung cancer typifies the challenges of shared decision-making in oncology. With a limited prognosis for survival, the increasingly numerous and complex treatment options must continually be weighed against...
3.
Deis N, Unsold L, Siegle A, Krisam J, Thomas M, Villalobos M
Trials
. 2023 May;
24(1):356.
PMID: 37231417
Background: Shared decision-making (SDM), which increases the patient's well-being, adherence, and success of treatment, is becoming increasingly important in medicine and especially in oncology. To empower patients to participate more...
4.
Siegle A, Unsold L, Deis N, Krug K, Bossert J, Krisam J, et al.
Support Care Cancer
. 2022 Dec;
31(1):77.
PMID: 36547732
Purpose: Oncological societies advocate the continuity of care, specialized communication, and early integration of palliative care. To comply with these recommendations, an interprofessional, longitudinally-structured communication concept, the Milestone Communication Approach...
5.
Krug K, Bossert J, Mollinger S, Deis N, Unsold L, Siegle A, et al.
BMC Palliat Care
. 2022 May;
21(1):89.
PMID: 35614425
Background: An innovative patient-centred interprofessional communication concept with advanced lung cancer patients (Heidelberg Milestone Communication Approach, MCA) has been developed and implemented. Role changes and interprofessional communication are challenging in...
6.
Villalobos M, Deis N, Wesselmann S, Seufferlein T, Ehlers F, Mahler C, et al.
Gesundheitswesen
. 2021 Apr;
84(10):968-970.
PMID: 33862649
The National Cancer Plan emphasises the importance of medical communication and calls for its integration into medical education and training. In this context, the Milestone Communication Approach meets the communicative...
7.
Krug K, Bossert J, Deis N, Krisam J, Villalobos M, Siegle A, et al.
Oncologist
. 2021 Apr;
26(8):e1445-e1459.
PMID: 33860592
Background: To address the support needs of newly diagnosed patients with lung cancer with limited prognosis, the Milestone Communication Approach (MCA) was developed and implemented. The main elements of the...
8.
Bossert J, Forstner J, Villalobos M, Siegle A, Jung C, Deis N, et al.
BMJ Open
. 2020 Aug;
10(8):e036495.
PMID: 32753449
Background: Patients with lung cancer with comorbidity often require treatment and care by different health professionals, in different settings and at different points in time during the course of the...
9.
Deis N, Koch C, Dreimuller N, Gaitzsch E, Weisskircher J, Junger J, et al.
GMS J Med Educ
. 2020 Apr;
37(1):Doc3.
PMID: 32270017
Insufficient risk competence of physicians, conflicts of interests from interactions with pharmaceutical companies, and the often distorted presentation of benefits and risks of therapies compromise the advising of patients by...
10.
Bossert J, Wensing M, Thomas M, Villalobos M, Jung C, Siegle A, et al.
BMC Palliat Care
. 2020 Feb;
19(1):21.
PMID: 32070311
Background: Despite improvements in diagnostics and therapy, the majority of lung tumours are diagnosed at advanced stage IV with a poor prognosis. Due to the nature of an incurable disease,...